PROTEIN ALTERNATIVES S.L.
Contact information
PROTEIN ALTERNATIVES S.L.
Juan Ignacio Imbaud - CEO
Ronda de Poniente 16, 1º A-F, Tres Cantos, C.P. 28760
Madrid
Madrid
918 047 322
Areas of activities
- Biodrugs
- Biomarkers
- In vitro diagnostics
- Oncology
- Animal health / Veterinary
- CRO / CMO / SMO
ProAlt is a biotechnology company that develops innovative products for the treatment, early diagnosis and prognosis of colorectal cancer. The company has three business divisions: Diagnostics, Therapy, and the contract research, development and manufacturing services (CRO/CMO). Our mission is to provide therapeutic options to patients with more aggressive and advanced tumors.
Products and services
- PA661: humanized anti-CDH17 (cadherin 17) monoclonal antibody for the treatment of liver metastasis from colorectal cancer (mCRC); in early preclinical phase.
- PA554: anti-IL12Ra2 (interleukin 13 receptos alpha 2) monoclonal antibody for the treatment of liver metastasis from colorectal cancer (mCRC) and glioblastoma (GBM); in early preclinical phase.
- PROFILUX: detection of lung cancer in patients´saliva and/or blood.
- COLOPROOF: genetic-based test in paraffinized tissue samples of patients (SEC6 genetic signature) to determine the risk of recurrence (prognosis) and predict response to chemotherapy (treatment guidance).
- CRO/CMO services: design, development and production of recombinant proteins, antibodies and inmunoassays, for diagnosis, therapy and other applications.
Areas of interest for future collaborations
Collaborations/alliances with biopharmaceutical companies for the clinical development of therapeutics antibodies PA661 and PA554 for the treatment of metastatic colorectal cancer.
Search for Investors.
Search for partners to co-develop the COLOPROOF prognostic test.